Affiliation:
1. National Institute of Unani Medicine, Begaluru, India
Abstract
Aim of the study: To evaluate the efficacy of Majoon Muṣaffī-i-Khūn (MMK) in cyclophosphamide-induced thrombocytopenia in male Sprague Dawley rats.
Material and Methods: Thrombocytopenia was induced by administration of Cyclophosphamide (25 mg/kg, 3 days, SC). Simultaneously, the animals were treated with MMK (300 and 600 mg/kg) orally and continued for three weeks. After completion of treatment, blood samples were collected by retro-orbital puncture and analyzed for WBC, RBC, Hb, and platelet counts, with bleeding and clotting time. MMK insignificantly increased the platelets, WBC, RBC, and Hb with a significant decreased in bleeding (p<0.001; p<0.05) and clotting times (P<0.01, P<0.001) which was altered by cyclophosphamide.
Results: The results demonstrated that MMK improved platelet counts, clotting, and bleeding time as well as restored the altered level of WBC, RBC, and Hb.
Conclusion: Based on the above results it can be concluded that the hydroalcoholic extract of MMK may have the potential to normalize the blood composition effectively.
Reference29 articles.
1. Visentin G.P, Liu C.Y. Drug-Induced Thrombocytopenia. Hematology/ Oncology Clinics of North America. 2007; 21(4): 685-696.
2. Fauci A.S, Kasper D.L, Hauser S.L, et al. Harrison's principles of internal medicine. Longo DL, editor. New York: Mcgraw-hill; 2012.
3. Erkurt M.A, Kaya E, Berber I, et al. Thrombocytopenia in adults. J Hematol. 2012; 1(2-3):44-53.
4. Kim E.J, Lim K.M, Kim K.Y, Bae O.N, Noh J.Y. Doxorubicin‐induced platelet cytotoxicity: a new contributory factor for doxorubicin‐mediated thrombocytopenia. J Thromb Haem. 2009; 7(7): 1172-1183.
5. Greenberg E.M, Kaled E.S. Thrombocytopenia. Critical Care Nursing Clinics of North America. 2013; 25(4): 427-434.